as 12-24-2024 1:42pm EST
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 434.0M | IPO Year: | N/A |
Target Price: | $29.14 | AVG Volume (30 days): | 681.3K |
Analyst Decision: | Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.76 | EPS Growth: | N/A |
52 Week Low/High: | $3.02 - $53.79 | Next Earning Date: | 11-07-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
QTTB Breaking Stock News: Dive into QTTB Ticker-Specific Updates for Smart Investing
TipRanks
12 days ago
Investor's Business Daily
13 days ago
PR Newswire
14 days ago
Simply Wall St.
20 days ago
PR Newswire
2 months ago
PR Newswire
2 months ago
PR Newswire
2 months ago
PR Newswire
4 months ago
The information presented on this page, "QTTB Q32 Bio Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.